Abstract library

22 results for "esophageal stricture".
#848 Zollinger-Ellison Syndrome: The Esophageal Stricture as a Rare and Severe Complication
Introduction: Zollinger-Ellison Syndrome (ZES) is caused by tumoral hypersecretion of gastrin, inducing gastric hyperchlorhydria and complicated peptic ulcer disease. Esophageal strictures are rare in ZES, due to early PPI treatment.
Conference: 11th Annual ENETS Conference (2014)
Category: Surgical treatment
Presenting Author: Claudio Pasquali
Authors:
#1500 Analysis of Oesophageal Neuroendocrine Tumour Outcomes
Introduction: Oesophageal Neuroendocrine Tumours(NETs) are rare neoplasms accounting for <2% of Gastroenteropancreatic NET(GEP NETs).
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Dr Apostolos Koffas
Authors:
Keywords: oesophageal nec
#1678 Multicenter Retrospective Analysis of Clinical and Pathological Features of Gastroesophageal Junction Neuroendocrine Neoplasm(GEJ-NEN)
Introduction: GEJ-NEN is mostly poorly differentiated NEC with poor prognosis.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Panpan Zhang
Authors:
#426 An Esophageal Gastrointestinal Stromal Tumor (GIST) in a Patient with MEN-1 Related Pancreatic Gastrinoma
Introduction: Both multiple endocrine neoplasia type 1 (MEN1)-related-gastrinomas and Gastrointestinal Stromal Tumors (GISTs) are rare neoplasms, and their association has been rarely reported.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Roberta E Rossi
Authors:
#386 A Prospective Evaluation of the Effects of Chronic Proton Pump Inhibitor Use on Plasma Biomarker Levels in Humans
Introduction: Proton pump inhibitors (PPIs) are used primarily to treat gastroesophageal reflux disease. PPI-induced achlorhydria increases circulating gastrin and chromogranin A (CGA). CGA is a widely used biomarker for the diagnosis and follow-up for gut-based neuroendocrine tumors (NETs). PPI-induced increases in CGA or gastrin may falsely suggest the presence of a NET when none exists. Pancreastatin, a fragment of CGA, is also commonly used to diagnose and follow NETs.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Eugene Woltering
Authors:
#443 Neuroendocrine Carcinoma (NEC) and Composite Exocrine-Neuroendocrine Carcinoma (CENEC) of the Stomach: A Clinicopathological Review of 58 Cases
Introduction: NEC of the stomach is an uncommon tumor accounting for 0.5% of all gastric carcinomas and about 6% of gastric NETs. CENEC contain both areas of NEC and conventional carcinoma. The histological diagnosis is difficult.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Vladimir Khomyakov
Authors:
#649 Poorly Differentiated Rectal Neuroendocrine Tumors: A Report of Three Cases
Introduction: Rectal neuroendocrine tumors (NETs) are rarely seen, representing only 1% to 2% of all rectal tumors, and 17% gastrointestinal NETs. They are classified by site of tumor origin and by degree of differentiation.
Conference: 10th Annual ENETS Conference (2013)
Category: Pathology, grading, staging
Presenting Author: Arzu Yaren
Authors:
Keywords: rectum NEC
#669 Incidence of Second Malignancy in Patients with Neuroendocrine Tumors (NETs) of the Ileum and Colon (MGC)
Introduction: Increased incidence of second malignancy is observed in NETs (Kamp et al 2012).
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Professor Joy Ardill
Authors:
#722 Isolation and Whole Genome Amplification of Single Circulating Tumor Cells in Neuroendocrine Tumors: A Pilot Study
Introduction: We have previously demonstrated that Circulating Tumor Cells (CTCs) can be detected in patients with neuroendocrine tumors (NET) and that their presence is prognostic. Downstream analysis of CTCs provides an opportunity to explore their potential as biomarker for targeted therapy. Here we present initial data which demonstrates that molecular profiling can be successfully performed on single CTCs from patients with NETs
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr Dalvinder Mandair
Authors:
#1069 Gastric Neuroendocrine Neoplasms and Long-Term Proton Pump Inhibitors: Need for a Revision of Classifications?
Introduction: Gastric neuroendocrine neoplasm (gNENs) include three types: type 1 and 2 related to hypergastrinemia due to chronic atrophic gastritis(CAG) or Zollinger-Ellison syndrome (ZES) respectively, and type 3 normogastrinemic and more aggressive. Few cases of gNENs in patients taking proton pump inhibitors (PPI) have been reported
Conference: 12th Annual ENETS Conference (2015)
Category: Clinical cases/reports
Presenting Author: MD Federica Cavalcoli
Authors:
Keywords: PPI, gNEN, classification, CAG